Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder

Monthly subcutaneous buprenorphine depot treatment appears to have a similar safety profile to sublingual buprenorphine. It also appears to have high retention rates and low levels of illicit opioid use.